Apollomics Inc - Class A
Research Apollomics Inc - Class A (APLM) on Bullrun: market cap USD 47.22M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPLM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 47.22M
- Financial periodFY2025
- RevenueUSD 8.50M
- Net income-USD 10.94M
- Free cash flow-USD 10.37M
Valuation Snapshot
latest market cap is USD 47.22M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 8.50M | -USD 10.94M | -USD 10.37M | n/a | n/a | USD 3.28M | USD 643.00K | -USD 3.19M |
| FY2024 | USD 0 | -USD 53.86M | -USD 28.77M | n/a | -52.8 | USD 9.77M | USD 966.00K | USD 4.86M |
| FY2023 | USD 0 | -USD 172.60M | -USD 43.22M | n/a | -231.99 | USD 32.06M | USD 4.66M | USD 41.23M |
| FY2022 | USD 0 | -USD 240.81M | -USD 43.19M | n/a | -0.37 | USD 32.68M | USD 991.00K | -USD 448.12M |
| FY2021 | USD 0 | -USD 94.80M | -USD 50.86M | n/a | -1.18 | USD 46.74M | USD 1.04M | -USD 212.86M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 47.22M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 40.13M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.75M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 86.35M | n/a | n/a | n/a |
About Apollomics Inc - Class A
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Apollomics Inc - Class A's market cap?
Apollomics Inc - Class A's market capitalization is USD 47.22M.
What does Apollomics Inc - Class A do?
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.